Fluvoxamine attenuates inflammation in experimental sepsis via novel non-canonical pathways.

Sepsis is characterized by a dysregulated systemic inflammatory response to infection and remains a major global health challenge, underscoring the need for novel therapeutic strategies. Drug repurposing offers a promising strategy, and fluvoxamine (…

Preview only. Read the full abstract at the source